公开(公告)号：US11634490B2

公开(公告)日：2023-04-25

申请号：US17058076

申请日：2019-06-14

Applicant: Accurus Biosciences, Inc.

Inventor： Haishan Lin ,  Yi Zhang

IPC: A61K39/00 ,  A61K39/395 ,  G01N33/53 ,  C12N5/02 ,  C12N5/20 ,  C07K16/00 ,  C07K16/46 ,  C07K16/28

Abstract: Provided are anti-CD47 antibodies or fragments thereof that can bind to the extra cellular domain of the CD47 protein. The antibodies or fragments thereof can effectively block the interaction between human CD47 and its ligand SIRP alpha and enhance the phagocytosis activity of macrophages to engulf cancer cells. Some of these antibodies or fragments do not induce in vitro hemagglutination and therefore can be suitably used as therapeutic agents with reduced off-target effects.

公开(公告)号：US12054543B2

公开(公告)日：2024-08-06

申请号：US17262351

申请日：2019-07-24

Applicant: ACCURUS BIOSCIENCES, INC.

Inventor： Haishan Lin ,  Richard Zhang

IPC: C07K16/28 ,  A61K47/68 ,  C07K14/705 ,  C07K14/725 ,  G01N33/68

CPC classification number: C07K16/28 ,  A61K47/6849 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70578 ,  G01N33/6854 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/33

Abstract: Provided herein are novel anti-CLDN 18.2 antibodies and chimeric antigen receptors (CAR), cells or compositions comprising the same, vector or plasmid encoding anti-CLDN 18.2 CAR, anti-CLDN 18.2 antibody-drug conjugates (ADCs), bispecific antibodies containing anti-CLDN 18.2 antibodies, and methods for producing the same, or using the same for detecting or treating ovarian cancer or prostate cancer. Also provided herein are anti-CLDN 18.2 antibodies, compositions comprising the same, nucleic acid sequence encoding the same, and a kit for detecting CLDN 18.2.

公开(公告)号：US20240336680A1

公开(公告)日：2024-10-10

申请号：US18753205

申请日：2024-06-25

Applicant: ACCURUS BIOSCIENCES, INC.

Inventor： Haishan Lin ,  Richard Zhang

IPC: C07K16/28 ,  A61K47/68 ,  C07K14/705 ,  C07K14/725 ,  G01N33/68

CPC classification number: C07K16/28 ,  A61K47/6849 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70578 ,  G01N33/6854 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/33

Abstract: Provided herein are novel anti-CLDN 18.2 antibodies and chimeric antigen receptors (CAR), cells or compositions comprising the same, vector or plasmid encoding anti-CLDN 18.2 CAR, anti-CLDN18.2 antibody-drug conjugates (ADCs), bispecific antibodies containing anti-CLDN 18.2 antibody, and methods for producing the same, or using the same for detecting or treating ovarian cancer or prostate cancer. Also provided herein are anti-CLDN 18.2 antibody, compositions comprising the same, nucleic acid sequence encoding the same, and a kit for detecting CLDN 18.2.

公开(公告)号：US20210214433A1

公开(公告)日：2021-07-15

申请号：US17262351

申请日：2019-07-24

Applicant: ACCURUS BIOSCIENCES, INC.

Inventor： Haishan Lin ,  Richard Zhang

IPC: C07K16/28 ,  C07K14/705 ,  C07K14/725 ,  G01N33/68 ,  A61K47/68

Abstract: Provided herein are novel anti-CLDN 18.2 antibodies and chimeric antigen receptors (CAR), cells or compositions comprising the same, vector or plasmid encoding anti-CLDN 18.2 CAR, anti-CLDN 18.2 antibody-drug conjugates (ADCs), bispecific antibodies containing anti-CLDN 18.2 antibody, and methods for producing the same, or using the same for detecting or treating ovarian cancer or prostate cancer. Also provided herein are anti-CLDN 18.2 antibody, compositions comprising the same, nucleic acid sequence encoding the same, and a kit for detecting CLDN 18.2.

公开(公告)号：US20210206850A1

公开(公告)日：2021-07-08

申请号：US17058076

申请日：2019-06-14

Applicant: Accurus Biosciences, Inc.

Inventor： Haishan Lin ,  Yi Zhang

IPC: C07K16/28

Abstract: Provided are anti-CD47 antibodies or fragments thereof that can bind to the extra cellular domain of the CD47 protein. The antibodies or fragments thereof can effectively block the interaction between human CD47 and its ligand SIRP alpha and enhance the phagocytosis activity of macrophages to engulf cancer cells. Some of these antibodies or fragments do not induce in vitro hemagglutination and therefore can be suitably used as therapeutic agents with reduced off-target effects.